 |
 Video: What is a Stock Split?
|
|
|
| Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, in vivo validation capabilities and a cross-functional team to discover medicines. Co.'s potential medicines include: REC-994 for the treatment of cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 for the treatment of familial adenomatous polyposis; REC-3599 for the treatment of GM2 gangliosidosis; REC-3964 for the treatment of C. difficile colitis; REC-64917 for neural or systemic inflammation; and multiple simultaneous programs in fibrosis developing with Bayer AG. According to our Recursion Pharmaceuticals stock split history records, Recursion Pharmaceuticals has had 0 splits. | |
|
Recursion Pharmaceuticals (RXRX) has 0 splits in our Recursion Pharmaceuticals stock split history database.
Looking at the Recursion Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Recursion Pharmaceuticals shares, starting with a $10,000 purchase of RXRX, presented on a split-history-adjusted basis factoring in the complete Recursion Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/19/2021 |
|
| End date: |
05/26/2023 |
|
| Start price/share: |
$28.00 |
|
| End price/share: |
$8.93 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-68.11% |
|
| Average Annual Total Return: |
-41.95% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$3,189.05 |
|
| Years: |
2.10 |
|
|
|
|
|
